Good News! WestVac Biopharma Recombinant COVID-19 Vaccine (Sf9 cell) - Coviccine Listed in the "Immunization Schedule for Second COVID-19 Booster Dose”
2022-12-15
On December 13, 2022, the State Council's Integrated Group of Joint Prevention and Control Mechanism for Response to COVID-19 issued the "Immunization Schedule for Second COVID-19 Booster Dose " (hereinafter referred to as the "Schedule"). The Recombinant COVID -19 Vaccine (Sf9 cell) - Coviccine™ developed and produced by WestVac Biopharma Co., Ltd. has been listed in the Schedule as the heterologous booster immunization vaccine followed by 3-dose inactivated vaccine.
It's also emphasized that a second COVID-19 booster dose can be given to people at high risk of infection, people over 60 years of age, people with more serious underlying diseases and people with low immunity.It's stated in the Schedule that, based on the progress of vaccine R&D, the vaccines approved for conditional marketing or emergency use can be used as a second COVID-19 booster dose, with priority given to heterologous booster immunization, or the vaccines containing the Omicron variant or showing good cross-immunity to the Omicron variants can be used as a second COVID-19 booster dose. According to the Schedule, for those who have already received 3 doses of inactivated vaccine, they can choose Recombinant COVID-19 Vaccine (Sf9 cell) - CoviccineTM as additional heterologous booster immunization. It’s also emphasized that a second COVID-19 booster dose can be given to people at high risk of infection, people over 60 years of age, people with more serious underlying diseases and people with low immunity.
Recombinant COVID-19 Vaccine (Sf9 cell) - CoviccineTM is a recombinant novel coronavirus vaccine with high efficacy in preventing COVID-19 caused by multiple Omicron variants, which was approved for emergency use by national authorities on December 2. A clinical study has shown that heterologous booster vaccination with 1 dose of CoviccineTM can induce high levels of specific neutralizing antibodies against the SARS-CoV-2 original variant and Omicron variants in healthy subjects who have completed 3 doses of inactivated COVID-19 vaccine for 6 months or more. After heterologous booster vaccination, the neutralizing antibodies against variants such as Omicron BA.1, BA.2, BA.4 and BA.5 in the serum of subjects in the CoviccineTM group increased by 50 times or more. It demonstrated CoviccineTM’s strengths in protecting key populations such as people at high risk of infection, people over 60 years of age and people with underlying diseases from infecting COVID-19. Due to its good safety and tolerability profile, the Recombinant COVID-19 Vaccine (Sf9 cell) – CoviccineTM is one of the preferred vaccines for heterologous booster immunization at present.
At present, WestVac Biopharma is actively implementing the heterologous booster immunization in different regions of China to offer a safe and effective solution to protect people from infecting coronavirus variants and further build up the immune barrier to reduce the incidence of symptomatic COVID-19 infection and moderate and severe hospitalization cases and deaths. WestVac would solider on and fight against the pandamics.
